At 52 weeks , compared with sitagliptin 100-mg treatment , canagliflozin 300 mg demonstrated superior glycemic control at all thresholds of A1C , and superior BP , BMI , and weight-related quality measures ; there was no difference in LDL-C quality measure attainment .